Competition [between pharma companies in MENA] is only getting more intense due to the increasing demand and decreasing cost of manufacturing
In Conversation
It is important that if a patient is diagnosed, the treatment is always readily available, so we are working with the relevant stakeholders, such as payers,…
Having built my experience in the US, I learnt that it does not matter who you are, you must always be learning and be an expert…
It is a strategic imperative that Hong Kong develops its unique system for drug registration as this will, in turn, foster a more comprehensive ecosystem, and…
Overall, the ecosystem for biotech is on the rise [in Hong Kong], and this brings a bevvy of new opportunities
The Hong Kong Genome Project is helping patients and their families by identifying the causes of their diseases and formulating personalised treatment plans
Hong Kong is a two-way gateway between the rest of the world and mainland China
Belgium offers a skilled labourforce, with a high educational level, who are mostly multilingual. In a similar way to other countries of smaller size, its people…
[Post-COVID], people in Hong Kong now are more aware of what phase 1, 2, 3 trials are, why randomization, double-blinding and placebo are applied, and are…
The UAE has the right ecosystem; it is one of the few places in the world that is positioned to leapfrog significantly in healthcare
Looking at the experiences of countries like the UK, Germany, and Italy with HTA, it is clear that if we put in place such a model…
Our focus at Novartis Gulf is clear, we aim to transform the standard of care for twice as many patients, twice as fast
